Literature DB >> 20146633

PAK as a therapeutic target in gastric cancer.

Xiaodong Li1, Funan Liu, Feng Li.   

Abstract

IMPORTANCE OF THE FIELD: Gastric cancer is one of the most common causes of cancer death worldwide. P21-activated kinases (PAKs), regulators of cancer-cell signalling networks, play fundamental roles in a range of cellular processes through their binding partners or kinase substrates. AREAS COVERED IN THIS REVIEW: The complex regulation of PAKs through their upstream or downstream effectors in human cancers, especially in gastric cancer, are described and the identified inhibitors of PAKs are summarized. WHAT THE READERS WILL GAIN: The structural differences and activation mechanisms between two subgroups of PAK are described. Both groups of PAKs play complicated and important roles in human gastric cancer, which indicated a possible way for us to identify the specific inhibitors targeting PAKs for gastric cancer. TAKE HOME MESSAGE: PAKs play important roles in progression of many cancer types, the full mechanisms of PAKs in gastric cancer are still unclear. It seems there are different roles for two groups of PAKs in cancers. Group I PAKs play their functions mostly through their specific substrates, however, many binding partners that are independent of phosphorylation by group II PAKs were identified. Finding specific inhibitors of PAKs will help us discover the roles of PAKs and target these kinases in human gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20146633     DOI: 10.1517/14728221003642019

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  14 in total

1.  Pak2 regulates hematopoietic progenitor cell proliferation, survival, and differentiation.

Authors:  Yi Zeng; Hal E Broxmeyer; Karl Staser; Brahmananda Reddy Chitteti; Su-Jung Park; Seongmin Hahn; Scott Cooper; Zejin Sun; Li Jiang; XianLin Yang; Jin Yuan; Rachelle Kosoff; George Sandusky; Edward F Srour; Jonathan Chernoff; D Wade Clapp
Journal:  Stem Cells       Date:  2015-05       Impact factor: 6.277

2.  P21-activated kinase 4 overexpression in metastatic gastric cancer patients.

Authors:  Hee Kyung Ahn; Jiryeon Jang; Jeeyun Lee; Park Se Hoon; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Kyoung-Mee Kim; Won Ki Kang
Journal:  Transl Oncol       Date:  2011-12-01       Impact factor: 4.243

3.  Activated Pak4 expression correlates with poor prognosis in human gastric cancer patients.

Authors:  Danni Li; Ye Zhang; Zhi Li; Ximing Wang; Xiujuan Qu; Yunpeng Liu
Journal:  Tumour Biol       Date:  2015-06-30

4.  PAK5-mediated E47 phosphorylation promotes epithelial-mesenchymal transition and metastasis of colon cancer.

Authors:  G Zhu; X Li; B Guo; Q Ke; M Dong; F Li
Journal:  Oncogene       Date:  2015-07-27       Impact factor: 9.867

5.  p21-Activated kinase 6 (PAK6) inhibits prostate cancer growth via phosphorylation of androgen receptor and tumorigenic E3 ligase murine double minute-2 (Mdm2).

Authors:  Tong Liu; Yang Li; Hui Gu; Ge Zhu; Jiabin Li; Liu Cao; Feng Li
Journal:  J Biol Chem       Date:  2012-11-06       Impact factor: 5.157

6.  IRX1 influences peritoneal spreading and metastasis via inhibiting BDKRB2-dependent neovascularization on gastric cancer.

Authors:  J Jiang; W Liu; X Guo; R Zhang; Q Zhi; J Ji; J Zhang; X Chen; J Li; J Zhang; Q Gu; B Liu; Z Zhu; Y Yu
Journal:  Oncogene       Date:  2011-05-23       Impact factor: 9.867

7.  GATA1 induces epithelial-mesenchymal transition in breast cancer cells through PAK5 oncogenic signaling.

Authors:  Yang Li; Qiang Ke; Yangguang Shao; Ge Zhu; Yanshu Li; Nanxi Geng; Feng Jin; Feng Li
Journal:  Oncotarget       Date:  2015-02-28

8.  PAK1-mediated MORC2 phosphorylation promotes gastric tumorigenesis.

Authors:  Guiling Wang; Yanyan Song; Tong Liu; Chunyu Wang; Qing Zhang; Furong Liu; Xinze Cai; Zhifeng Miao; Hongde Xu; Huimian Xu; Liu Cao; Feng Li
Journal:  Oncotarget       Date:  2015

9.  PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.

Authors:  Xueqiong Fu; Jiarui Feng; Duan Zeng; Yu Ding; Changshou Yu; Bing Yang
Journal:  Biosci Rep       Date:  2014-04-01       Impact factor: 3.840

10.  PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway.

Authors:  Xiang-Rong Shu; Jing Wu; He Sun; Li-Qun Chi; Jin-Huan Wang
Journal:  Diagn Pathol       Date:  2015-09-28       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.